Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06216301 · ClinicalTrials.gov registry record · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by NovoCure.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 734
- Enrollment target
- 20
- Study locations
NCT06216301 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by NovoCure. The registered enrollment target is 734 participants, above the 369-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06216301, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by NovoCure.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 734 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DEVICE NovoTTF-200T
- DRUG Platinum based chemotherapy
Study Locations (20)
Illinois
- Northwest Oncology & Hematology - Barrington
- Elmhurst Hospital Nancy Knowles Cancer Center - Elmhurst
- Edward Cancer Center - Naperville
- Cancer Treatment Centers of America (CTCA) - Zion
Missouri
- Luminis Health Radiation Oncology - Anne Arundel Health System - Annapolis
- University of Kansas Cancer Center - North - Kansas City
- University of Kansas Cancer Center - Lee's Summit - Lee's Summit
- University of Kansas Cancer Center - Overland Park - Overland
California
- St. Jude Herritage Medical Group - Fullerton
- Hoag Family Cancer Institute - Hoag Memorial Hospital - Newport Beach
- Sutter Institute for Medical Research - Sacramento
New York
- New York Cancer & Blood Specialists (NYCBS) - New Hyde Park
- New York Cancer & Blood Specialists (NYCBS) - New York
- University of Rochester Medical Center - Rochester
Florida
- Florida Cancer Affiliates - Ocala Oncology - Ocala
- Moffitt Cancer Center - Tampa
Alabama
- Central Alabama Research - Birmingham
Arizona
- Western Regional Medical Center, LLC - Goodyear
Indiana
- Franciscan Health Indianapolis - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06216301
The ClinicalTrials.gov registry entry for NCT06216301 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 369-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (99% higher). The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06216301 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT06216301 about?
NCT06216301 is a clinical study titled "LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC". This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts o...
What is the current status of trial NCT06216301?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2024-07-31. Estimated completion is 2028-10.
What conditions does trial NCT06216301 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT06216301?
The interventions under investigation include: Pembrolizumab (DRUG), NovoTTF-200T (DEVICE), Platinum based chemotherapy (DRUG).
Who is sponsoring clinical trial NCT06216301?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06216301 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.